Skip to main
MYO
MYO logo

Myomo (MYO) Stock Forecast & Price Target

Myomo (MYO) Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Myomo's reimbursement pipeline demonstrated consistent growth, increasing from 1,389 units in Q4 to 1,669 units in the current quarter, indicating a positive trend in the company's ability to secure reimbursements for its innovative myoelectric orthosis products. The company has strategically redirected its focus toward the large Medicare market, which comprises approximately 22% of its projected revenue in 2024, positioning itself for substantial growth. Furthermore, a recent positive ruling from the Centers for Medicare & Medicaid Services to include the MyoPro device in Medicare Part B benefits significantly expands its potential market, underscoring the increasing acceptance and demand for Myomo's technology.

Bears say

Myomo Inc. has lowered its 2025 revenue guidance to $40 – 42 million, a significant decrease from the previous estimate of $50 – 53 million, indicating a more pessimistic outlook for financial performance. Additionally, the company is experiencing a decline in its backlog of insurance-authorized orders, which decreased from 272 in Q4 to 208, suggesting challenges in demand and pipeline conversion. Furthermore, recent marketing efforts and pipeline quality have failed to meet expectations, further exacerbating concerns about lead generation and overall growth potential.

Myomo (MYO) has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Myomo and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Myomo (MYO) Forecast

Analysts have given Myomo (MYO) a Strong Buy based on their latest research and market trends.

According to 3 analysts, Myomo (MYO) has a Strong Buy consensus rating as of Dec 16, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $7.67, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $7.67, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Myomo (MYO)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.